Frontlight ResearchEarly access
SuspendedPhase 1/2
Efficacy and Safety Evaluation of IBI188 in Combination With Demethylating Agents in Treatment of Patients With Acute Myeloid Leukemia
Key facts
- Who runs it
- Innovent Biologics (Suzhou) Co. Ltd.
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- Phase
- Phase 1/2
- People taking part
- 222 people, planned
- Started
- 25 Sept 2020
- Ended
- 31 Dec 2024
- Type of study
- Interventional, 2 groups
- Treatments tested
- IBI188
- Azacitidine
- Decitabine
- Record updated
- 23 October 2023
- Why it stopped
- Pause for changes in development strategies
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 10 criteriaShow less
Who can take part
- AML patients diagnosed according to WHO AML diagnostic criteria in 2016 (except M3-type and BCR-ABL positive AML)
- Relapsed// refractory AML( ≥18 ys) or newly diagnosed elderly AML unfit for intensive chemotherapy( ≥60 ys)
- Age ≥18 years old, gender not limited
- ECOG score of 0-2
- Adequate organ function
Who cannot take part
- Major surgery and vaccine treatment within 4 weeks
- Uncontrolled concurrent diseases
- A history of myeloproliferative diseases (including myelofibrosis, primary thrombocytosis, and true red) Cytosis, chronic myelocytic leukemia) or acute myeloid white blood with BCR-ABL1 translocation Patients
- Acute promyelocytic leukemia, myeloid sarcoma, acute heterozygous leukemia, CMML(accelerated phase and blast phase)
- Pregnant or breastfeeding female subjects
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The study is to evaluate safety, tolerability and composite CR of IBI188 plus Demethylating Agents in acute myeloid leukemia
The 2 groups in the trial
- IBI188+azacitidineTreatment being tested
1L unfit AML receive IBI188 every week by intravenous(IV) and azacitidine daily in Day 1-7 of each four weeks(Q4W) by subcutaneous(IH)
Treatment: IBI188 and Azacitidine
- IBI188+decitabineTreatment being tested
R/R AML receive IBI188 every week by intravenous(IV) and decitabine daily in Day 1-10 of each four weeks(Q4W) by subcutaneous(IH)
Treatment: IBI188 and Decitabine
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase Ib Study Evaluating the Safety and Efficacy of IBI188 in Combination With Demethylating Agents in Subjects With Acute Myeloid Leukemia
- Record updated
- 23 October 2023